Lexagene Holdings (CVE: LXG- OTCQB: LXXGF) CEO Jack Regan joined Steve Darling from Proactive with news the company is planning to use their patented MiQLa system to investigate novel variants of the SARS-Cov-2 which is the pathogen that causes COVID-19.
Dr. Regan telling Proactive this investigation of the variants becomes very important to make sure vaccines will remain effective as the new strains appear to be about 70% more contagious, making containment that much more challenging.